BioSpace News Archive

Following several clinical failures for its candidates Roxadustat and pamrevlumab, FibroGen CEO Enrique Conterno is stepping down for “personal reasons,” the company announced Tuesday.

The Federal Trade Commission’s increased scrutiny of mergers has now hit IQVIA, whose proposed acquisition of Propel Media has been challenged by the watchdog agency.

While GlaxoSmithKline is anticipating a slower uptake of respiratory syncytial virus vaccine Arexvy, CEO Emma Walmsley said Wednesday the company is pinning much of its growth on the vaccine’s performance.

In a recent study of the U.S. states with the best and worst job markets, nine came out on top. Read on for details about the life sciences industry and jobs available in each state.

The Phase III trial, which will test the companies’ mRNA-based personalized cancer vaccine and Merck’s blockbuster Keytruda checkpoint inhibitor, is slated for completion by the fall of 2029.

On the heels of a European Union investigation, the UK’s health agency is reviewing safety data for GLP-1 receptor agonists after reports of self-harm and suicidal thoughts.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announces the addition of two distinguished experts to its Scientific Advisory Board.

Just one week after returning from Inspired Spine’s training lab in Germany, the internationally renowned neurosurgeon, Dr. Hamid Abbasi, showcased the pioneering Trans-Kambin OLLIF Procedure in multiple states by presenting to the Seattle Science Foundation and leading a cadaver lab at Swedish Hospital last Saturday, July 22nd.

LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance.

Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D., MBA, a veteran dealmaker and strategic leader with 25+ years of biotech and pharmaceutical industry experience, as Chief Business Officer effective September 8, 2023.